Cesca Therapeutics, a Rancho Cordova, Calif.-based autologous cell-based regenerative medicine company, released the study results on its technology for treating non-union fractures.
The study includes 17 patients who were treated with bone marrow concentrate for non-union fractures. Researchers used Cesca Therapeutics' proprietary technology to process bone marrow aspirate at the point of care.
Journal of Stem Cells Research, Development and Therapy published the results.
Here are four observations:
1. The bone marrow concentrate is designed to stimulate bone regeneration and healing of the fracture.
2. Fourteen of the patients experienced bone regeneration and fracture healing.
3. The bone marrow concentrate is administered in a single sitting, decreasing infection risk.
4. Researchers noted no adverse reactions during or following the procedure.
"Cell therapy using bone marrow concentrate represents a promising new method for treating atrophic non-union fractures in patients with a history of failed primary surgical intervention," said Dr. Venkatesh Ponemone, study director. "We are encouraged by these results and look forward to making this method routinely available."